United States Code

42 U.S.C. § 285c-6

Advisory council subcommittees

Statute Watch

Get an alert when any bill in Congress would change this law — and every time it moves.

Sign in to follow →

Bills that would change it 9

  • HR 9169 PKD Cures Act Amends its part · introduced · 119th Congress
  • HR 8601 Liver Illness Visibility, Education, and Research Act of 2024 Amends · introduced · 118th Congress
  • HR 7585 Health Equity and Accountability Act of 2022 Amends its part 285c-6(a)(1) · introduced · 117th Congress
  • S 4486 Health Equity and Accountability Act of 2022 Amends its part 285c-6(a)(1) · introduced · 117th Congress
  • HR 5675 Liver Illness Visibility, Education, and Research Act of 2021 Amends · introduced · 117th Congress
  • S 3041 Liver Illness Visibility, Education, and Research Act of 2021 Amends · introduced · 117th Congress
  • S 3074 Liver Illness Visibility, Education, and Research Act of 2019 Amends · introduced · 116th Congress
  • HR 3016 Liver Illness Visibility, Education, and Research Act of 2019 Amends · introduced · 116th Congress
  • HR 5942 Health Equity and Accountability Act of 2018 Amends its part · introduced · 115th Congress

The law today

From the official United States Code, current through Public Law 119-121.

There are established within the advisory council for the Institute appointed under section 284a of this title a subcommittee on diabetes and endocrine and metabolic diseases, a subcommittee on digestive diseases and nutrition, and a subcommittee on kidney, urologic, and hematologic diseases. The subcommittees shall be composed of members of the advisory council who are outstanding in the diagnosis, prevention, and treatment of the diseases for which the subcommittees are established and members of the advisory council who are leaders in the fields of education and public affairs. The subcommittees are authorized to review applications made to the Director of the Institute for grants for research and training projects relating to the diagnosis, prevention, and treatment of the diseases for which the subcommittees are established and shall recommend to the advisory council those applications and contracts that the subcommittees determine will best carry out the purposes of the Institute. The subcommittees shall also review and evaluate the diabetes and endocrine and metabolic diseases, digestive diseases and nutrition, and kidney, urologic, and hematologic diseases programs of the Institute and recommend to the advisory council such changes in the administration of such programs as the subcommittees determine are necessary.
Official text at uscode.house.gov ↗